{"created":"2023-06-19T10:43:22.273672+00:00","id":3599,"links":{},"metadata":{"_buckets":{"deposit":"760fc03b-fe36-4447-bc02-e5088dede13b"},"_deposit":{"created_by":11,"id":"3599","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3599"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003599","sets":["30:50:193"]},"author_link":["3728","7955","7953","7957","7958","7954","7956","7959"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-05","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"2198","bibliographicPageStart":"2184","bibliographicVolumeNumber":"37","bibliographic_titles":[{},{"bibliographic_title":"Advances in therapy","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"大路, 正人"}],"nameIdentifiers":[{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: \nTo compare visual outcomes and treatment burden between intravitreally administered aflibercept (IVT-AFL) and ranibizumab (RBZ) treat-and-extend (T&E) regimens in patients with wet age-related macular degeneration (wAMD) at 2 years. ","subitem_description_type":"Abstract"},{"subitem_description":"Methods:\nA systematic literature review was carried out in Medline, EMBASE, and CENTRAL in October 2018. Matching-adjusted indirect comparison (MAIC) and/or individual patient data meta-regression was used to connect ALTAIR (assessing IVT-AFL T&E) with other studies, adjusting for between-trial differences in baseline visual acuity and age or baseline visual acuity, age, and polypoidal choroidal vasculopathy (PCV) status. Sensitivity analyses were conducted to test the robustness of the results, including direct MAIC between IVT-AFL T&E (ALTAIR) and RBZ T&E (CANTREAT and TREX-AMD trials). ","subitem_description_type":"Abstract"},{"subitem_description":"Results: \nSix randomized controlled trials (RCTs) (ALTAIR, VIEW 1 and 2, CATT, CANTREAT, and TREX) were included in the analysis. IVT-AFL T&E was assessed in one study, ALTAIR (n = 255), while RBZ T&E was assessed in two trials (n = 327). At 2 years, the median difference (95% credibility interval) between IVT-AFL T&E and RBZ T&E regarding the numbers of Early Treatment Diabetic Retinopathy Study (ETDRS) letters gained was not significant (M1: - 2.29 [- 8.10, 3.58]; M2: - 0.55 [- 6.34, 5.29]). IVT-AFL T&E was associated with significantly fewer injections than RBZ-T&E (M1: - 6.12 [- 7.60, - 4.65]; M2: - 5.93 [- 7.42, - 4.45]). Results of the sensitivity analyses were consistent with the main scenarios.","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion: \nPatients with wAMD receiving an IVT-AFL T&E regimen achieved and maintained improvement in visual acuity with fewer injections over 2 years compared with RBZ T&E. IVT-AFL T&E may therefore serve as the optimal therapy for wAMD, as it was associated with clinical efficacy and minimized treatment burden. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Nature"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"32222903","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1007/s12325-020-01298-x "}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s12325-020-01298-x","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"©The Author(s) 2020"}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1865-8652","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"OHJI, Masahito"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"LANZETTA, Paolo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOROBELNIK, Jean-Francois"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"WOJCIECHOWSKI  , Piotr"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TAIEB, Vanessa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"DESCHASEAUX, Celine"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"JANER, Daniel "}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TUCKMANTEL, Claudia"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-06-17"}],"displaytype":"detail","filename":"s12325-020-01298-x.pdf","filesize":[{"value":"725.7 kB"}],"format":"application/pdf","license_note":"This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"s12325-020-01298-x","url":"https://shiga-med.repo.nii.ac.jp/record/3599/files/s12325-020-01298-x.pdf"},"version_id":"208becb6-62a7-48b4-b2b5-176bda7631b2"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Intravitreal anti-vascular endothelial growth factor therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Network meta-analysis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Ophthalmology","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Wet age-related macular degeneration","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison."}]},"item_type_id":"4","owner":"11","path":["193"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-06-17"},"publish_date":"2020-06-17","publish_status":"0","recid":"3599","relation_version_is_last":true,"title":["Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T12:18:31.906503+00:00"}